

## Truth in Testimony Disclosure Form

In accordance with Rule XI, clause 2(g)(5)\*, of the *Rules of the House of Representatives*, witnesses are asked to disclose the following information. Please complete this form electronically by filling in the provided blanks.

**Committee:** Science, Space, and Technology

**Subcommittee:** Oversight

**Hearing Date:** September 23, 2020

**Hearing Subject:**

"Data for Decision-Making: Responsible Management of Data during COVID-19 and Beyond". The purpose of the hearing is to explore COVID-19 data management at the local, state, and Federal level, including how relevant stakeholders are collecting, analyzing, and reporting data that informs COVID-19 research and decision making.

**Witness Name:** Lisa L. Maragakis, MD, MPH

**Position/Title:** Senior Director of Infection Prevention, Johns Hopkins Health System

**Witness Type:** ☐ Governmental ☒ Non-governmental

**Are you representing yourself or an organization?** ☐ Self ☒ Organization

**If you are representing an organization, please list what entity or entities you are representing:**

The Society for Healthcare Epidemiology of America

**If you are a non-governmental witness, please list any federal grants, cooperative agreements, or contracts (including subgrants or subcontracts) related to the hearing's subject matter that you or the organization(s) you represent at this hearing received in the current calendar year and previous two calendar years. Include the source and amount of each grant, cooperative agreement, or contract. If necessary, attach additional sheet(s) to provide more information.**

Please see attached list of federal grants, cooperative agreements, and contracts

**If you are a non-governmental witness, please list any contracts or payments originating with a foreign government and related to the hearing's subject matter that you or the organization(s) you represent at this hearing received in the current year and previous two calendar years. Include the amount and country of origin of each contract or payment. If necessary, attach additional sheet(s) to provide more information.**

None

## **FUNDING**

### **Extramural Sponsorship**

#### ***Current Grants and Contracts***

9/15 – 9/20	ASPR Region 3 Ebola and Other Special Pathogens Treatment Center (in collaboration with DHMH and ASPR Region 3) Grant # ASPR EP-U3R-15-002 Assistant Secretary for Preparedness and Response (ASPR) Role: PI
3/16 – 3/21	Ethical, Legal and Social Issues for Precision Medicine and Infectious Disease 1 RM1 HG009038-01 National Human Genome Research Institute, NIH Co-Principal Investigators: Dr. Gail Geller and Dr. Jeffrey Kahn Role: Co-investigator, Effort 10%
9/30/18-9/29/20	<i>Clostridium difficile</i> Over Testing (C-DOT) Improvement initiative; a Multi-Prevention Epicenter Collaborative Project U01 CK000554-01 CDC \$1,087,274 PI: Clare Rock Role: Co-Investigator; The goal of the project is to develop and implement a human factors engineering approach to reduce inappropriate testing for <i>Clostridium difficile</i> using prompts in the electronic health record.
9/18 – 9/20	Epicenters for the Prevention of Healthcare Associated Infections HAIs)- Cycle II: <i>Clostridium difficile</i> Prevention and Risk Adjustment; Hospital-onset Bacteremia Grant # U54 CK000447-01 Centers for Disease Control and Prevention (CDC) Principal Investigator: Dr. Clare Rock Role: Co-investigator, Effort: 5%
9/30/18-9/29/20	Epicenter for the Prevention of Healthcare-Associated Infections (HAI); Cycle II Multicenter Program Studies U01 CK000556-01 CDC \$1,100,000 Role: Site Investigator
2/7/20 – 2/6/25	The Comprehensive Unit-based safety Program (CUSP) for Methicillin-Resistant <i>Staphylococcus Aureus</i> (MRSA) Prevention HHSP75P120R00008 AHRQ \$1,813,358 Role: PI The purpose of this task order is to measurably decrease methicillin-resistant <i>staphylococcus aureus</i> (MRSA) invasive infections in multiple settings (ICUs, non-ICUs, high-risk surgical patients, and long-term care facilities) in a

SST\_TTF Attachment  
Maragakis, Lisa L.  
September 20, 2020

nationwide implementation project through the use of an adaptation of the Comprehensive Unit-based Safety Program (CUSP).

***Pending***

- 6/1/20-5/31/21      The Johns Hopkins Epicenters for the Prevention of Healthcare-Associated Infections Response to the COVID-19 Pandemic  
Supplemental COVID-19(Cosgrove and Rock)  
CDC  
\$790,699  
Role: Co-Investigator
- 9/30/20-9/29/25      Johns Hopkins Prevention Epicenter: Transdisciplinary Research Approaches to Prevent Healthcare Associated Infections and Antibiotic Resistance (TRAP HAI & AR)  
RFA-CK-20-004  
CDC  
\$5,571,737  
PIs: Cosgrove and Rock  
Role: Co-Investigator

***Previous Grants and Contracts***

- 6/16/13-4/30/20      Ethical, Legal & Social Implications of “Precision Medicine” in Infection Control Disease  
RM1HG009038-01  
NHGRI CEER II  
\$640,055  
PIs: Geller and Kahn  
Role: Co-Investigator  
The major goal of CEER is devoted to scholarship, research, and career development in the ethical, legal, social, historical and policy issues confronting the application of genomics to the prevention, outbreak control, and treatment of infectious diseases, which pose an enormous health burden in the U.S globally.
- 5/18/15-5/17/20      ASPR Region 3 Ebola and Other Special Pathogens Treatment Center (in collaboration with DHMH and ASPR Region 3)  
EP-U3R-15-002  
ASPR-DHHS  
\$828,000  
Role: PI  
The goals of the project are to improve health care system preparedness for Ebola and other Infectious diseases and to develop a regional hospital network for Ebola patient care.
- 7/15 – 6/19      Removing barriers to hand hygiene and glove compliance: evaluation of two novel time-efficient interventions  
R01 HS024108-01  
Agency for Healthcare Research and Quality (AHRQ)  
PI: Dr. Kerri Thom  
Role: Co-Investigator, Effort: 7%

SST\_TTF Attachment  
Maragakis, Lisa L.  
September 20, 2020

9/15 – 9/18

Epicenters for the Prevention of Healthcare Associated Infections HAIs)- Cycle  
II: Applying Human Factors and Mathematical Modeling Approaches to Prevent  
Transmission of High-Consequence Pathogens  
U54 CK000447-01  
Centers for Disease Control and Prevention (CDC)  
Co-Principal Investigators: Dr. Peter Pronovost and Dr. Lisa Maragakis  
Role: Co-PI, Effort: 5%